Objective To explore the effectiveness and clinical application value of non-invasive hemodynamic monitoring in heart failure complicated with reduced ejection fraction (HFrEF) patients treated with levosimendan.

Methods A total of 86 patients with HFrEF were selected, and randomly divided into two groups: the control group and the observation group, with 43 cases in each group. The control group were treated with conventional Western medicine, while the observation group were treated with levosimendan injection through micropump for 24 hours on the basis of standard treatment. The treatment course for both groups was one week. Meanwhile, the double-finger sleeve double-anchored upper arm calibration CNAP^®Monitor 500 continuous blood pressure monitoring instrument (CNAP^®) from CNSystems of Austria was used for continuous monitoring. The multiple hemodynamic changes, changes in cardiac function indicators and incidence of adverse reactions in two groups before medication and after 7 days of medication were recorded.

Results After treatment, the levels of cardiac output (CO) and stroke volume (SV) in the observation group were higher than those in control group (P ＜ 0.05). The level of pulse pressure variation rate (PPV) in the observation group was lower than that in control group. There was no statistical significance in the peripheral vascular resistance (SVR) between two groups after treatment (P ＞ 0.05). The levels of systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) in the observation group were lower than those in control group (P ＜ 0.05). In terms of cardiac function indicators, after treatment, the left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDD) in the observation group were higher than those in control group (P ＜ 0.05). There was no statistical significance in the left ventricular end-systolic diameter (LVESD) between two groups after treatment (P ＞ 0.05). The N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the observation group was lower than that in control group (P ＜ 0.01). There was no statistical significance in the incidence of adverse reactions between two groups (P ＞ 0.05).

Conclusions Levosimendan can enhance the therapeutic effect of HFrEF. CNAP is convenient to apply in clinical practice. It can monitor the cardiac function status of patients in real time and repeatedly, evaluate the therapeutic effect of heart failure patients in a timely manner, reduce the incidence of complications, effectively improve the prognosis of patients, and has strong practical value.